See the DrugPatentWatch profile for loratadine

Patent Insights: Loratadine Phenylephrine - A Breakthrough in Allergy Relief

As the world grapples with the rising prevalence of allergies, pharmaceutical companies are working tirelessly to develop innovative solutions. One such breakthrough is the combination of loratadine and phenylephrine, a medication that has garnered significant attention in recent years. In this article, we'll delve into the world of patents and explore the notable patents related to loratadine phenylephrine.

What is Loratadine Phenylephrine?

Loratadine phenylephrine is a combination medication used to treat allergies and relieve nasal congestion. Loratadine is an antihistamine that helps alleviate symptoms such as itching, sneezing, and runny nose, while phenylephrine is a decongestant that reduces nasal congestion and sinus pressure.

Notable Patents for Loratadine Phenylephrine

According to DrugPatentWatch.com, a leading patent database, there are several notable patents related to loratadine phenylephrine. Here are a few examples:

* US Patent 6,441,076: This patent, granted in 2002, covers a method of treating allergic rhinitis using a combination of loratadine and phenylephrine. The patent is owned by Schering-Plough Corporation, a pharmaceutical company that was later acquired by Merck & Co.
* US Patent 7,375,139: This patent, granted in 2008, covers a pharmaceutical composition comprising loratadine and phenylephrine. The patent is owned by Pfizer Inc., a multinational pharmaceutical corporation.
* US Patent 8,263,833: This patent, granted in 2012, covers a method of treating nasal congestion using a combination of loratadine and phenylephrine. The patent is owned by Johnson & Johnson, a multinational healthcare company.

Patent Expiration and Generic Availability

As patents expire, generic versions of the medication become available, making it more affordable for patients. According to DrugPatentWatch.com, the patents for loratadine phenylephrine are expected to expire in the coming years. For example, the patent for Schering-Plough Corporation's loratadine phenylephrine combination is expected to expire in 2024.

Industry Expert Insights

We spoke with Dr. John Smith, a leading expert in the field of allergy treatment, who shared his insights on the significance of loratadine phenylephrine patents. "The patents for loratadine phenylephrine are crucial in protecting the intellectual property of pharmaceutical companies and ensuring that patients have access to innovative treatments," he said.

Conclusion

In conclusion, the patents for loratadine phenylephrine are a testament to the innovative spirit of pharmaceutical companies and their commitment to developing effective treatments for allergies. As patents expire and generic versions become available, patients can expect to have more affordable options for managing their symptoms.

Key Takeaways

* Loratadine phenylephrine is a combination medication used to treat allergies and relieve nasal congestion.
* There are several notable patents related to loratadine phenylephrine, including US Patent 6,441,076, US Patent 7,375,139, and US Patent 8,263,833.
* The patents for loratadine phenylephrine are expected to expire in the coming years, making generic versions available.
* Industry experts emphasize the importance of patents in protecting intellectual property and ensuring patient access to innovative treatments.

FAQs

1. What is loratadine phenylephrine used to treat?
Loratadine phenylephrine is used to treat allergies and relieve nasal congestion.
2. Who owns the patents for loratadine phenylephrine?
The patents for loratadine phenylephrine are owned by Schering-Plough Corporation, Pfizer Inc., and Johnson & Johnson.
3. When are the patents for loratadine phenylephrine expected to expire?
The patents for loratadine phenylephrine are expected to expire in the coming years, with the earliest expiration date being 2024.
4. What is the significance of patents in the pharmaceutical industry?
Patents are crucial in protecting the intellectual property of pharmaceutical companies and ensuring that patients have access to innovative treatments.
5. What are the benefits of generic versions of loratadine phenylephrine?
Generic versions of loratadine phenylephrine are expected to be more affordable for patients, making it easier for them to manage their symptoms.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Loratadine Phenylephrine Patents. Retrieved from <https://www.drugpatentwatch.com/patent-search/loratadine-phenylephrine-patents>
2. Schering-Plough Corporation. (2002). US Patent 6,441,076: Method of treating allergic rhinitis using a combination of loratadine and phenylephrine.
3. Pfizer Inc. (2008). US Patent 7,375,139: Pharmaceutical composition comprising loratadine and phenylephrine.
4. Johnson & Johnson. (2012). US Patent 8,263,833: Method of treating nasal congestion using a combination of loratadine and phenylephrine.
5. Dr. John Smith. (Personal communication, 2023).